Sunitinib glucuronate

Overview

Sunitinib (SU 11248) glucuronate is a multi-targeted receptor tyrosine kinase inhibitor with IC 50 s of 80 nM and 2 nM for VEGFR2 and PDGFRβ , respectively. Sunitinib glucuronate, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation.

Application

Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Autophagy | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Autophagy | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > PDGFR | Products > Signaling Pathways > VEGFR | Products > Signaling Pathways > IRE1 | Products > Signaling Pathways > Mitophagy

Product Information

• Catalog No.: HY-10255C
• CAS No.: 1818285-48-1
• Molecular Formula: C28H37FN4O9
• Molecular Weight: 592.61
• Purity: 95.0%
• Storage: Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Availability: In-stock

Source

Original product source